Arvinas · 1 month ago
Co-op Biology-Oncology
New Haven - CT
Full-time
Onsite
New GradArvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. The Spring 2026 Oncology Biology Co-Op position focuses on evaluating the effect of novel heterobifunctional degrader molecules on intracellular oncology targets and validating newly proposed targets for potential degrader discovery efforts.
BiotechnologyHealth CarePharmaceuticalTherapeutics
No H1B
Responsibilities
Cell culture including sterile technique for mammalian cell lines
Functional genomics approaches (such as CRISPR KO, siRNA/shRNA KD) to interrogate targets to understand their biological function, especially at scale or in a hypothesis-driven way
Cellular assays to monitor activity of degrader compounds (such as Western blot, JESS, high-content imaging, HiBiT, NanoBRET)
Establishing and developing new assays to detect target engagement and small molecule binding to targets in vitro and in cells
Data analysis and interpretation, as well as presenting data in team meetings
Meeting with key stakeholders outside of the project team to devise future experiments for downstream applications
Qualification
Required
The candidate should be a highly motivated fast learner with flexibility and ability to multi-task, as well as a good lab citizen
Experience in cell culture is required
Experience with immunoblotting and genetic perturbation assay skills are required
Ability to work full-time (40 hours per week)
Arvinas will not be providing VISA sponsorship for this position now or in the future. You must have the ability to work without a need for a current or future VISA sponsorship
Preferred
Prior lab experience highly preferred
Previous oncology experience is preferred
Knowledge of ubiquitin-based proteasomal degradation is desired, but not a pre-requisite
Experience in the computational analysis and interpretation of omics datasets, such as RNA-seq and proteomics, to inform biological hypotheses, target identification, and mechanistic understanding is considered a plus
Preference to Master's / PhD student currently enrolled in a program with a concentration in cell biology, immunology, pharmacology, biology, or related fields
Company
Arvinas
Arvinas advances therapies degrading disease-causing proteins for life-threatening diseases, from discovery to commercialization.
Founded in 2013
201-500 employees
Funding
Current Stage
Public CompanyTotal Funding
$461.6MKey Investors
Logos CapitalNextech Invest
2025-08-15Post Ipo Equity
2023-11-27Post Ipo Equity· $350M
2018-09-26IPO
Leadership Team
Angela M. Cacace
Chief Scientific Officer
Craig M. Crews
Founder
Recent News
Canaan Partners
2025-12-03
2025-11-11
Company data provided by crunchbase